ExchangeCME

09/29/2026

Referral does not necessarily mean stepping away from the patient’s care.

The CAR T Companion Tool outlines the phases of the CAR T journey and helps community oncology teams understand potential coordination touchpoints before treatment, during care at the treatment center, and through shared follow-up.

Explore the care pathway: https://cart-comptool.com

09/22/2026

When CAR T may be appropriate to consider, the next conversation matters.

The CAR T Companion Tool provides an educational framework to help community oncology teams review clinical indications and treatment history, prepare patients for treatment-center consultation, and discuss potential next steps.

Explore referral guidance: https://cart-comptool.com

09/15/2026

Patients may turn first to the oncology professionals they already know and trust when they have questions about CAR T therapy.

The CAR T Companion Tool helps community oncology teams review FDA-approved indications, access organized therapy information, and prepare for informed conversations with patients and caregivers.

Explore CAR T therapy guidance: https://cart-comptool.com

For educational purposes only. The tool does not determine patient eligibility or recommend treatment.

CAR-T Compass offers clear CAR-T therapy resources, glossary terms, treatment guidance, and wallet cards across 14 pages for patients and clinicians.

09/08/2026

The community oncology team can play an important role throughout the CAR T journey.

The CAR T Companion Tool provides practical, evidence-anchored guidance to help teams recognize when CAR T may be considered, prepare for referral conversations, understand what happens at the treatment center, and support coordinated follow-up.

Explore the tool: https://cart-comptool.com

For educational purposes only. Final eligibility is determined by the treating CAR T center.

07/26/2026

Organize appointments, treatments, symptoms, and priorities in one free companion. Explore the free tool: https://mbc-companion.org

04/01/2026

🔬 Save the Date: IL-33 in the SpotlightJoin us at ATS 2026 for an expert-led discussion on emerging IL-33 pathways and their role in COPD and acute respiratory infections.📍 Hilton Orlando (Florida Ballroom 1–4)
🗓 Monday, May 18
⏰ 6:30 – 8:30 PM ET🎓 Earn 1.5 CME credits
🍽 Dinner will be servedFaculty:
• Jonathan M. Hand, MD
• Dave Singh, MD
• Tom Wilkinson, MA, MBBS, PhD
Explore novel mechanisms and evolving clinical implications shaping respiratory care.🔗 Registration coming soon—save your seat.

03/02/2026

🧬 EGPA and Hypereosinophilic Syndrome: Why IL-5 Matters

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare eosinophilic disorders associated with multi-organ damage.

At the center of both diseases: activated eosinophils.

Key mechanistic insights:

• Cytotoxic granule protein release → tissue injury
• IL-5 regulates eosinophil maturation, mobilization, and survival
• Tissue eosinophils do not recirculate and persist via local cytokine support
• Activated eosinophils contribute to endothelial dysfunction and thrombotic risk

EGPA phenotype distinction:

🔹 ANCA-positive → vasculitic features
🔹 ANCA-negative → eosinophil-driven tissue infiltration

Mechanism-based therapies targeting IL-5 or its receptor are approved or in development.

🎥 Now available on demand.
For more information, visit:
https://buff.ly/XXPaogs

03/01/2026

We are live from !
✔️ Live, in person
✔️ Live webcast available

🔗 https://bit.ly/EGPAHES

03/01/2026

Attending in person or virtually? Sign up for a breakfast session on EGPA & HES, featuring expert discussions on pathophysiology, diagnostics, and biological treatments. ✔️ Available live on-site ✔️ Streamed webcast option 🔗 https://bit.ly/EGPAHES

02/25/2026

At or joining from afar?
Register for a breakfast symposium on EGPA & HES with expert insights on pathophysiology, diagnosis, and biologic treatment.
✔️ Live, in person
✔️ Live webcast available
🔗 https://bit.ly/EGPAHES